版本:
中国

BRIEF-Puma Biotechnology presents interim results of Phase II CONTROL trial of PB272

April 4 Puma Biotechnology Inc:

* Puma Biotechnology presents interim results of Phase II CONTROL trial of PB272 in extended adjuvant treatment of HER2-positive early stage breast cancer at the 2017 AACR annual meeting

* Results of Phase II CONTROL trial showed incidence of grade 3 diarrhea for 137 patients who received loperamide prophylaxis was 30.7%

* For 137 patients who received loperamide prophylaxis in Phase II CONTROL trial, 20.4% discontinued neratinib due to diarrhea

* Reductions seen in incidence of severe neratinib-related diarrhea in CONTROL trial Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐